A patient with BRAF N581S mutation-positive lung adenocarcinoma demonstrates durable response to combined anlotinib and tislelizumab: a case report and literature review
Authors
Ying Liu,
Mingyang LiYu Guo,
Zhiyong Zhang,
Liuyang Du,
Xiaotong Zhang,
Ying‐Ping Wang,
Dong Zhang,
Lingfei Xue,
Binhua Lei,
Jing Su,
Ruiwen Zhang,
Jiaohong Chen,
Xiangqian Zhang,
Qingge Jia +13 authors
,
Chuntao Tian Tip Tip